Close Menu
Trade Verdict
  • Home
  • Latest News
  • Investing
  • Personal Finance
  • Retirement
  • Economy
  • Stocks
  • Bonds
  • Commodities
  • Cryptocurrencies
Facebook X (Twitter) Instagram
Trade Verdict
  • Latest News
  • Investing
  • Personal Finance
  • Retirement
  • Economy
Facebook X (Twitter) Instagram
Trade Verdict
Stocks

United Therapeutics Company – Particular Name

EditorialBy EditorialSeptember 28, 2025No Comments2 Mins Read

[ad_1]

United Therapeutics Company – Particular Name

Firm Members

Harrison Silvers – Supervisor of Investor Relations
Leigh Peterson – Govt Vice President of Product Improvement & Xenotransplantation
Martine Rothblatt – Founder, Chairman & CEO

Convention Name Members

Steven D. Nathan
Olivia Brayer – Cantor Fitzgerald & Co., Analysis Division
Andreas Argyrides – Oppenheimer & Co. Inc., Analysis Division
Joseph Thome – TD Cowen, Analysis Division
Lisa Walter – RBC Capital Markets, Analysis Division
Jessica Fye – JPMorgan Chase & Co, Analysis Division
Jason Gerberry – BofA Securities, Analysis Division

Presentation

Operator

Good afternoon, and welcome to the United Therapeutics Company Part 3 TETON-2 Outcomes Convention Name. My identify is Drew, and I might be your convention operator right now. [Operator Instructions] Please be aware that this name is being recorded. I’d now like to show the webcast over to Harry Silvers, Investor Relations Supervisor at United Therapeutics.

Harrison Silvers
Supervisor of Investor Relations

Thanks, Drew. Good day, everybody. It’s my pleasure to welcome you to the United Therapeutics Company Part 3 TETON-2 outcomes convention name.

Remarks right now will embrace forward-looking statements representing our expectations or beliefs concerning future occasions. These statements contain dangers and uncertainties that will trigger precise outcomes to vary materially. Our newest SEC filings, together with Kinds 10-Ok and 10-Q, include extra data on these dangers and uncertainties. We assume no obligation to replace forward-looking statements.

As we speak’s remarks could talk about the progress and outcomes of medical trials or different developments with respect to our merchandise. These remarks are supposed solely to coach buyers and usually are not supposed to function the idea for medical decision-making or to counsel that any merchandise are secure and efficient for any unapproved or investigational makes use of. Full prescribing data for the merchandise is obtainable on our web site.

Accompanying me on right now’s name are Dr. Steve Nathan, Schar Chair of the Superior

[ad_2]

Editorial
  • Website

Related Posts

Why some staff will not profit from the deduction

December 24, 2025

GoodRx: The Tide Is Shifting Out Of This Firm's Favor (Downgrade)

December 24, 2025

Shares making the most important strikes premarket: NKE, DVAX, PATH

December 24, 2025

The Gabelli Gold Fund, Inc. Q3 2025 Commentary

December 24, 2025
Add A Comment
Leave A Reply Cancel Reply

Trade Verdict
Facebook X (Twitter) Instagram Pinterest
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Service
© 2026 Trade Verdict. All rights reserved by Trade Verdict.

Type above and press Enter to search. Press Esc to cancel.